Shares of Puma Biotechnology Inc (NASDAQ:PBYI) have been given an average recommendation of “Buy” by the eleven analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $130.67.
PBYI has been the topic of several recent analyst reports. Stifel Nicolaus raised their price target on shares of Puma Biotechnology from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, October 2nd. Credit Suisse Group reaffirmed an “outperform” rating and issued a $136.00 price target on shares of Puma Biotechnology in a research note on Wednesday, September 27th. BidaskClub raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 3rd. Leerink Swann raised their price target on shares of Puma Biotechnology to $140.00 and gave the stock an “outperform” rating in a research note on Friday, October 27th. Finally, Citigroup reaffirmed a “buy” rating and issued a $156.00 price target (up previously from $114.00) on shares of Puma Biotechnology in a research note on Thursday, October 5th.
In related news, insider Charles R. Eyler sold 1,322 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $105.46, for a total value of $139,418.12. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Richard Paul Bryce sold 15,000 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the completion of the transaction, the senior vice president now directly owns 42,239 shares in the company, valued at approximately $5,068,680. The disclosure for this sale can be found here. Company insiders own 21.10% of the company’s stock.
Institutional investors have recently modified their holdings of the business. New York State Common Retirement Fund grew its holdings in Puma Biotechnology by 4.7% during the 2nd quarter. New York State Common Retirement Fund now owns 32,247 shares of the biopharmaceutical company’s stock worth $2,818,000 after acquiring an additional 1,446 shares in the last quarter. Teacher Retirement System of Texas bought a new position in Puma Biotechnology during the 2nd quarter worth about $211,000. BlackRock Inc. grew its holdings in Puma Biotechnology by 5.0% during the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock worth $159,973,000 after acquiring an additional 86,924 shares in the last quarter. Prudential Financial Inc. bought a new position in Puma Biotechnology during the 2nd quarter worth about $302,000. Finally, Perceptive Advisors LLC grew its holdings in Puma Biotechnology by 26.0% during the 3rd quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock worth $110,627,000 after acquiring an additional 190,500 shares in the last quarter. Institutional investors own 96.00% of the company’s stock.
Shares of Puma Biotechnology (NASDAQ PBYI) traded up $2.20 on Monday, hitting $97.15. 625,437 shares of the stock traded hands, compared to its average volume of 1,077,062. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.50) by $0.43. The firm had revenue of $6.10 million during the quarter, compared to analysts’ expectations of $3.78 million. During the same period in the prior year, the company posted ($1.11) EPS. sell-side analysts expect that Puma Biotechnology will post -8.19 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/13/brokerages-set-puma-biotechnology-inc-pbyi-pt-at-130-67.html.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.